Introduction
Kavanagh demonstrated in the early 1950s that several fungal species of the genus Pleurotus produced substances that inhibit the activity of Staphylococcus aureus. Further to this, the antibacterial substance produced by Pleurotus mutilus (Clitopilus scyphoides) and Pleurotus passeckerianus (Clitopilus passeckerianus) was isolated in crystalline form and named pleuromutilin. 1, 2 Structural elucidation studies were first published in 1952, with Anchel correctly describing the molecular formula of pleuromutilin (C 22 H 34 O 5 ) and correctly assigning three of the five oxygen atoms as two non-phenolic hydroxyl groups and one hindered carbonyl group. 3 The remaining two oxygen atoms were tentatively assigned to a lactone ring; this was later corrected, and shown to be the ester functionality at C14. Independent work by Birch at the University of Abbreviations: Ac, acyl; AIBN, Azobisisobutyronitrile; Bn, benzyl; cap, caprolactamate; CYP, cytochrome P450; DIBAL, diisobutylaluminium hydride; DLP, dilauroyl peroxide; DMAP, N,N-dimethylaminopyridine; DMF, N,Ndimethylformamide; DMSO, dimethylsulfoxide; im, imidazole; HMDS, hexamethyldisilazane; HMPA, hexamethylphosphoramide; MBz, para-methylbenzoyl; Ms, methanesulfonyl; MOM, methoxymethyl; NHK, NozakieHiyamaeKishi; NMO, Nmethylmorpholine N-oxide; PCC, pyridinium chlorochromate; Piv, pivaloyl; py, pyridine; SAR, structureeactivity relationship; TBAF, tetrabutylammonium fluoride; TBAT, tetrabutylammonium triphenyldifluorosilicate; TBDPS, tert-butyldiphenylsilyl; TBS, tert-butyldimethylsilyl; TCDI, 1,1 0 -Thiocarbonyldiimidazole; TES, triethylsilyl; TFA, trifluoroacetic acid; TFAA, trifluoroacetic anhydride; THP, tetrahydropyran; TMS, trimethylsilyl; TPAP, tetrapropylammonium perruthenate; Ts, para-toluenesulfonyl; WHO, World Health Organisation. Manchester 4, 5 and Arigoni at the Swiss Federal Institute of Technology 6 culminated in the publication of the full and correct structure of (þ)-pleuromutilin (1) ( Fig. 1 ) and a proposed biosynthetic pathway, thus characterising pleuromutilin as the glycolic ester of the diterpene (þ)-mutilin (2) . The numbering of pleuromutilin described by Arigoni has become convention throughout pleuromutilin chemistry is shown in Fig. 1 . For simplicity this system will be used throughout this report.
The ever increasing emergence of multi-drug-resistant microorganisms has led to the World Health Organisation (WHO) issuing renewed pleas for action to be taken against antimicrobial resistance. 7 The development of new antibiotics has not kept pace with demand; for example, new cases of multi-drug-resistant tuberculosis alone account for around 150,000 deaths annually. 7 Since the publication of the structure and activity of pleuromutilin, much synthetic effort has been focused on the synthesis of analogues with increased activity and a more favourable pharmacokinetic profile. A handful of compounds are widely used in veterinary medicine and a single analogue has been licensed for topical use on humans. It was recently announced that BC-3781 will enter Phase III clinical trials and may offer the first systemic pleuromutilin antibiotic for human use. 8e12 All of the compounds either licensed or in clinical trials vary only in the C14 side chain. Despite this a wealth of chemistry, including complex structural modifications of the core, has been investigated. Total synthesis, however, presents the only tool for major re-structuring of the pleuromutilin core and several groups have attempted to gain synthetic access to the pleuromutilin core, with three total syntheses now reported.
Synthetic manipulation of pleuromutilin
This section of the review catalogues the synthetic manipulations of pleuromutilin, which will be presented in the following sections: selective functionalisation of the C14 hydroxyl, synthesis of metabolites and similar compounds, modification of the core, modification at C12 and modification at C13. Whilst this report does not aim to capture every chemical transformation performed on pleuromutilin or its derivatives, it will provide a useful guide to the reactivity of this structurally intriguing, densely functionalised and biologically important natural product.
Modification at C14
All of the pleuromutilin analogues currently used in veterinary ( Fig. 2A ) or human ( Fig. 2B ) medicine vary only in the C14 side chain, furthermore they have sulfur at C22 followed by a two-or three-carbon linker before a basic nitrogen functionality. More recently azamulin was not progressed beyond Phase I clinical trials due to poor water solubility; BC-3781, developed at Nabriva, is however progressing through clinical trials (Fig. 2C ).
Alternative analogues at C14 have been investigated including carbamate and acyl carbamate linkers. In this section the aim is to consider strategies and approaches to analogues of pleuromutilin and not repeat the excellent and extensive patent and structureeactivity relationship (SAR) reviews on the C14 side chain. 13e24 C14 Acyloxy derivatives of mutilin have been prepared, most commonly by activation of the primary alcohol of pleuromutilin (C22) as a tosylate 9a (R¼p-tol), followed by substitution with a thiol (X¼S), 25e56 amine (X¼NH) 52, 57, 58 or alcohol (X¼O) 43e45,59,60 to form 10 (Scheme 1A). This is the general procedure used for the synthesis of tiamulin (3) 61e63 and valnemulin (4) 64e70 ( Fig. 2A ). Alternatively the mesylate 9b (R¼Me) was also susceptible to substitution by a thiol (X¼S) 59,71e74 or amine (X¼NH). 75 Retapamulin (5) and a number of other analogues were synthesised by an alternate but similar approach: mesylpleuromutilin 9b (R¼Me) was substituted with thioacetic acid to give 10 (XR 0 ¼SAc) and treatment of 10 with tropine-3-mesylate in the presence of ethylenediamine cleaved the acetate and gave retapamulin (5) ( Fig. 2B ). 76 The stepwise strategy has also been reported whereby treatment of 10 (XR 0 ¼SAc) with ethylenediamine afforded pleuromutilin thiol 10 (XR 0 ¼SH), which could itself substitute a number of mesylates. 71,77e79 In an approach to rapidly investigate a number of pleuromutilin nucleoside conjugates, click chemistry was employed; tosylpleuromutilin 9a was substituted with sodium azide to form 10 (XR 0 ¼N 3 ), which underwent click chemistry with a range of nucleoside derived alkynes to form 1,2,3-triazole analogues of pleuromutilin. 80, 81 The azide 10 (XR 0 ¼N 3 ) has also been reduced to give aminopleuromutilin 10 (XR 0 ¼NH 2 ), which was converted to a range of analogues. 59 Further activation of the C22 position in tosylpleuromutilin 9a by conversion to the bromide or iodide 11 has also been reported (Scheme 1B). In these cases the halide has been substituted with a thiol (X¼S), amine (X¼NH 2 ) or alcohol (X¼O) to give 10. 27, 28, 40, 56, 60, 82 The modification of pleuromutilin is desirable as there is no need for protecting group chemistry. On the other hand, selective functionalisation of the C14 hydroxyl in mutilin is less straightforward as the C11 hydroxyl is considerably more reactive.
Berner demonstrated inversion of the stereochemistry at C4 with a concomitant 1,5-hydride shift from C11 to C3 to form 12 (Scheme 2), known colloquially as 4-epi-mutilin (vide infra, Scheme 12). 83 This compound has only one hydroxyl (at C14) and can therefore undergo reaction under a range of conditions to form C14 analogues of mutilin. 4-epi-Mutilin has been used to form acyl analogues of pleuromutilin such as 14 by treatment with the required acid chloride 59, 84 (Scheme 2A). Conversion of 13 to the desired mutilin analogue 14 was achieved using ZnCl 2 and HCl. This restored the C4 stereochemistry and a 1,5-hydride shift from C3 to C11 reformed the carbonyl and hydroxyl, respectively.
A number of groups have reported access to C14 carbamate analogues of pleuromutilin 14 (R¼NHR 0 ) through carbonochloridate 15 (Scheme 2B). Compound 15 has been prepared by treatment of 4-epi-mutilin 12 with trichloromethyl chloroformate, 85 phosgene, 86 or triphosgene. 87, 88 Compound 15 has then been converted to several different carbamates by reaction with various amines. Once again treatment with ZnCl 2 and HCl completes the synthesis of these analogues.
An alternate approach to C14 carbamates through 4-epi-mutilin 12 was reported in 2007. 89, 90 Treatment of 12 with sodium cyanate and trifluoroacetic acid lead to the formation of 4-epi-mutilin-14carbamate 16, which was acylated to give a range of acetylcarbamates. Yang has since reported a one-pot procedure for the synthesis of 4-epi-mutilin-14-acetylcarbamates using silver(I) cyanate and an acid chloride. 42,88,91e95 Further optimization to a process route was also reported and in that case an acetyl isocyanate was preformed and coupled with 4-epi-mutilin. 96 Alternatively, selective protection of the C11 hydroxyl of mutilin followed by reaction of the C14 hydroxyl has been reported. Strategies involving bis-acylation (C11 and C14) followed by mild cleavage of the C14 acetate were first reported. 92 However, more recently the trifluoroacetyl group has been employed as an easily cleaved protecting group that can be selectively installed at C11 (Scheme 3 Treatment of mutilin with TFAA and pyridine (Discovery route) or with trifluoroacetylimidazole (Process route) provided the C11 trifluoroacetyl mutilin 17, which has been shown to take part in several ester-forming reactions. 58, 97 The advantage of this strategy is that simple treatment of 18 with mild base will cleave the C11 trifluoroacetyl group and afford the desired pleuromutilin analogue 14. Intermediate 17 has also been used in a range of carbamate and acyl carbamate forming reactions, previously described with 4-epimutilin (Scheme 2). 42, 88, 92, 93, 97 Yang has reported the synthesis and biological data for a series of water-soluble phosphate prodrugs of pleuromutilin analogues, the most promising example bears the phosphate at a phenolic hydroxyl on a C14 carbamate side chain; however, Yang also reported an example of a C11 phosphate prodrug of a C14 carbamate pleuromutilin analogue. Both of these compounds were shown to be suitably soluble and stable in aqueous buffer, and the phenolic phosphate was metabolised to the active drug and exhibited comparable antibacterial activity to vancomycin in a mouse model. 42, 96 In 2001 Takle and co-workers at SmithKline Beecham reported an approach to C14 amido mutilin derivative 22 (Scheme 4). 85 Treatment of diacetylmutilin 19 with potassium tert-butoxide afforded the cyclopropyl mutilin derivative 20, which proved largely resistant to further reaction. However, treatment of 20 with sodium azide in DMF at 150 C led to the formation of 21, albeit in very low yield. Reduction of the azide in 21 proceeded with concomitant reduction of the C12 vinyl. This was followed by conversion of the C14 amine to an amide and saponification of the C11 acetate to give 22. The intermediate C14 amino mutilin has also been used in the synthesis of C14 acylurea analogues. Takle and coworkers have shown that these two C14 amino derived analogues have dramatically reduced antibacterial properties and therefore this analogue family was not investigated further.
Many C14 analogues of pleuromutilin (>3000) have been synthesised, however, only three have made it through clinical trials to medicinal use and only one for use on humans (topical).
Synthesis of metabolites and similar compounds
The metabolism of pleuromutilin has been mainly attributed to cytochrome P450 (CYP) dependant hydroxylation at either C2 (23) or C8 (24) of the tricyclic core (Scheme 5). These compounds are almost entirely devoid of biological activity. 98, 99 Metabolite 25 was also isolated and is the product of de-ethylation of the tiamulin side chain. This compound exhibits around 25% of the activity of tiamulin, metabolites that are active, but exhibit activity at a lower level than the parent antibiotic would be expected to select for antimicrobial resistance. 100 Several researchers have investigated synthetic access to the metabolites of pleuromutilin and also to compounds potentially blocked to metabolism. Hanson has investigated the biotransformation of pleuromutilin and mutilin using CYPs in whole cell cultures. 99, 101 Treatment of (þ)-pleuromutilin (1) with Cunninghamella echinulata SC 16162, a filamentous fungus, provided (2R)-hydroxy pleuromutilin 26 (Scheme 6A). Interestingly, the opposite epimer 27 is obtained upon treatment of (þ)-mutilin (2) under the same conditions (Scheme 6B). Hanson also reported access to a separable mixture of 2-, 7-and 8-hydroxy mutilins 27, 28 and 29, respectively, by treatment of mutilin with gram positive bacterium Streptomyces griseus SC 1754 or SC 13971, and preparative quantities of 28 and 29 were available by this method. Of course these biotransformations could not be carried out on pleuromutilin, due to its antibiotic nature.
Several studies have investigated the products of biotransformation of mutilin: C8 hydroxy mutilin derivatives (28) have been used to synthesise a number of analogues including a C8 keto derivative. However, the vast majority of these analogues have been shown to exhibit no antibacterial activity. 102e104 In an attempt to block the metabolism of pleuromutilin derivatives Yang reported the synthesis of (2S)-fluoro mutilin derivatives (32) from 2-diazo mutilin 31 (Scheme 7). Upon installation of a suitable C14 side chain, these compounds showed appreciable activity with respect to the parent compound. Yang also reported access to (2S)-hydroxy mutilin derivatives 35; as expected, considerable erosion of the activity was observed for these compounds. 5, 91, 97, 105, 106 Yang employed Berner's diazomutilin derivative 31 for the synthesis of both the fluoro and hydroxyl derivatives. Treatment of pleuromutilin with methylformate and sodium methoxide led to activation of C2 by formation of the 1,3-dicarbonyl 30. Upon treatment with tosyl azide in Et 3 N the a-diazoketo derivative 31 was formed and fluorination upon treatment with HF/pyridine formed 32. a-Diazoketone 31 was also treated with dichloroacetic acid to afford, after hydrolysis, the hydroxyl derivative 35.
The reactivity of the vinyl moiety at C12 can prove problematic for some transformations of pleuromutilin. Egger and Reinshagen 61, 107 reported that several methyl, ethyl derivatives, such as 36 (Scheme 8), had largely unchanged bioactivity with respect to the methyl, vinyl parents. Modifications of C12, first described by Arigoni and Birch during structural elucidation studies will be discussed later. However 19,20dihydropleuromutilin 36 has proved a useful starting material in the preparation of some analogues.
As part of a vast pleuromutilin programme at Sandoz, Berner described the synthesis of (2R)-hydroxy mutilin derivative 39 by selective reduction of 1,2-diketopleuromutilin 38, which in turn was available through Mannich reaction of pleuromutilin followed by ozonolysis of 37. The same intermediate (38) was employed en route to analogues in which the C3 carbonyl was transposed to C2 (41, Scheme 8). Isomerisation of 39 under basic conditions provided 40, acetylation of 40 and careful reduction then afforded mutilin derivative 41. 108 Axten has since reported a somewhat simplified procedure for the synthesis of diacetylated 41. Treatment of diacetyl mutilin derivative 42 with sodium borohydride reduced the C3 ketone selectively to the (3S)-hydroxy derivative 43. Upon mesylation and elimination, 44 was formed in high yield and oxidised selectively at the allylic position using catalytic dirhodium(II) caprolactamate, to give 45 in 40% yield; the corresponding allylic alcohol was also isolated in 47% yield. Dissolving metal reduction afforded the desired cyclopentanone product in 64% yield but as a mixture of the diacetate (20%) and the monoacetates 109 (Scheme 9).
Simple and scalable access to 2-hydroxy mutilin was not available until 2008 when Wang reported a Rubottom oxidation procedure (Scheme 10). Treatment of mutilin with lithium hexamethdisilazide and TMSCl selectively afforded the kinetic silyl enol ether 46, which was oxidised using m-CPBA. Commonly NaHCO 3 is employed to buffer the Rubottom oxidation, however, in this case issues of over-oxidation and irreproducibility were reported. This was partially due to the inhomogeneity of the reaction mixture. Buffering the reaction with acetic acid and pyridine offered improved yields and high reproducibility on kilogramme scale. Acidic hydrolysis of the remaining silyl ethers led to the formation of 27 in 78% yield after crystallisation. 110 As described above, several strategies aimed at mimicking nature in gaining oxidative access to C2 have been developed, however, the seemingly unactivated positions of metabolism on pleuromutilin derivatives (C7 and C8) have provided more of a challenge. Biotransformation has provided preparative access to metabolites for the investigation of C7 and C8 oxidised analogues of pleuromutilin and more recently the group of White has accessed C7 oxidised analogues.
White has developed a method for regio-and stereoselective oxidation of unactivated CeH bonds in a range of complex molecules, including pleuromutilin derivative 48 (Scheme 11). Oxidation using catalytic Fe-(S,S)-PDP proceeded at C7; the (7S)-hydroxy compound 49 was formed in 42% yield, with the keto product 50 isolated in 20% yield and 24% starting 48 recovered. 111, 112 
Modification of the core
The unique and sterically confined 5,6,8-tricyclic core of pleuromutilin is susceptible to alkyl and hydride shifts under certain conditions; the outcome can include inversion of stereochemistry or ring expansion or contraction. Some of these transformations have been observed as undesired by-products in reactions and some have offered valuable preparative access to mutilin derivatives.
In 1981 Berner reported conditions for the inversion of stereochemistry at C4; this afforded the 5,6-trans ring junction. The transformation proceeded in almost quantitative yield with a concomitant 1,5-hydride shift between C11 and C3 to afford 4-epipleuromutilin 51, bearing a carbonyl at C11 and a methoxyl at C3. Most interestingly, treatment of 51 with a Lewis acid initiated the reverse reaction to reform pleuromutilin (Scheme 12). 83 Scheme 9. Rhodium-mediated allylic oxidation to form C2-ketomutilin derivatives by Axten. Reagents: a. NaBH 4 , 98%; b. MsCl, Et 3 N, 87%; c. Rh 2 (cap) 4 , t-BuOOH, K 2 CO 3 , 40%. The reversibility of this process renders 4-epi-pleuromutilin 51 and also 4-epi-mutilin exciting alternative structures for the synthesis of a wealth of analogues; C3 is now protected, the reactivity of C11 is entirely altered (hydroxyl to carbonyl) and steric arguments have changed. 4-epi-Mutilin has been used in the synthesis of a range of C12, C13 (vide infra) and C14 (vide supra) mutilin derivatives.
Amongst other interesting modifications to the core, Birch reported a contraction of the eight-membered ring upon activation of the C11 hydroxyl as a leaving group (Scheme 13). 5 This reaction offered access to a novel 5,6,7-tricyclic ring system 53.
Birch also reported exhaustive ozonolysis of 53 to form 54 as a mixture of diastereoisomers. Whilst these compounds may have interesting bioactivity, this transformation has also been observed as an undesired pathway during the synthesis of pleuromutilin analogues.
Many analogues of pleuromutilin (including tiamulin) are accessed by activation of the C22 hydroxyl, as a mesylate or tosylate, and then substitution by a thiol (vide supra, Scheme 1). Selective mesylation of pleuromutilin can be achieved (primary C22 over secondary C11), however, any C11 mesylated pleuromutilin that is formed rapidly undergoes ring contraction to form compounds such as 53. 71 A group at Bristol-Myers Squibb required a large quantity of the differentially protected pleuromutilin 56 for a discovery project. MOM ether 56 is available in high yield by treatment of 55 with dimethoxymethane and P 4 O 10 (Scheme 14A). Use of a large excess of P 4 O 10 and extended reaction times led to the formation of byproducts 57 and 58 (Scheme 14B). 113, 114 Springer proposes that both 57 and 58 are formed through oxonium ion 59 (Scheme 15); initial cyclisation to form tetrahydropyran 60 was followed by migration of C11 to form the transfused tetrahydrofuran 61. Subsequent loss of H a led to the external alkene 62, which incorporated a second equivalent of methyl(methylene)oxonium and after loss of H b formed 58. Alternatively initial loss of H b afforded the internal alkene 57.
Birch also observed the autoxidation of diacetoxymutilin using potassium tert-butoxide and tert-butanol to afford a ring cleaved ketoacid, similar to 64 (Scheme 16). Under the conditions employed by Birch the C11 acetate was hydrolysed, this was followed by a transannular hydride shift from C11 to C4 to afford an 11-keto-4hydroxy derivative, which proceeded to form a d-lactone by cyclisation of the C4 hydroxyl with the pendant carboxylic acid. 5 This chemistry has since been optimised by Springer on 56, to afford differentially protected ketoacid 64 in 70% yield. Some of these 6,8bicyclic systems, exemplified by 65, have shown promising activity against Streptococcus pneumonia A49585. 105 In an attempt to block metabolism, Berner at Sandoz prepared 4,6,8-tricyclic mutilin derivatives from 68 (Scheme 17). 2-Diazomutilin 66 underwent efficient photo-Wolff rearrangement to give 67 in 77% yield. Following acetylation to give 68, treatment with lead(IV) acetate in benzene and pyridine gave a mixture of the arylated and acetoxy products 69 and 70, respectively. Acetate 70 was then simply converted into the 4,6,8-mutilin analogue 72. 115 Modification of the pleuromutilin core has offered access to alternative tricyclic and bicyclic analogues, some of which have been shown to possess interesting biological activity. This suggests that further investigation of pleuromutilin-inspired tricyclic compounds with alternate ring sizes may offer breakthroughs in the search for improved pleuromutilin-inspired antibacterials.
Modification at C12
Another handle for the modification of pleuromutilin is the C19e20 olefin at C12. Indeed, one of the first reactions reported on pleuromutilin was the dissolving metal reduction with lithium in methanol and ammonia, resulting in reduction of the C3 ketone and the C12 vinyl motif to give 73 (Scheme 18). 5, 6 Of course, catalytic hydrogenation of the olefin has since been reported as an approach to 19,20-dihydromutilin derivatives such as 74. 74 C12 Methyl, ethyl compounds of this type were shown to have largely unaltered activity with respect to their parent compounds. 61 Alternatively, the vinyl group is susceptible to oxidation; Birch and Arigoni both reported ozonolysis of this group in C11 keto mutilin 75. Treatment of the intermediate peroxides with hydrogen peroxide led to the carboxylic acid, which underwent decarboxylation under thermal conditions to give 76 (albeit in low yield) (Scheme 19). 5, 6 Birch went on to report that under basic conditions the enolate of the C11 carbonyl can take part in aldol chemistry with the C3 carbonyl to form the tetracyclic compound 77. 5
The process of vinyl cleavage has since been revisited by Berner 115 and later by Takadoi at Kyorin Pharmaceutical Co. Ltd., 60, 116, 117 for the synthesis of pleuromutilin analogues. Both investigated this chemistry using 4-epi-mutilin derivatives (51 and 81) (vide supra, Scheme 12), thus protecting the C3 carbonyl from unwanted aldol reactions. Berner employed ozonolysis to the aldehyde 78 and decarbonylation under basic conditions to give 79 (Scheme 20A). Berner demonstrated that 79 was selectively alkylated at C12 from the back face with ethyl bromide, after deprotonation with NaH, in 78% yield and that the glycolate ester at C14 of 79 could be modified to give the tiamulin side chain. Either directly or following modification, 79 was converted to 80 (or derivatives thereof) thus restoring the natural stereochemistry of pleuromutilin.
Using dihydroxylation and then base mediated fragmentation, Takadoi provided an alternate route to a similar 12-devinyl mutilin derivative 83 (Scheme 20B). Takadoi installed a number of groups at C12, including the propargyl group by alkylation with propargyl bromide to give 84; whilst an interesting derivative in its own right, the C12 propargyl also offers opportunity for further functionalisation. Takadoi also reported the addition of methyl para-toluenethiolsulfonate to form the 12-thiomethyl derivative 85. All of Takadoi's derivatives were then furnished with a suitable C14 side chain and the pleuromutilin stereochemistry restored (ZnCl 2 and HCl) before biological evaluation. 60, 116, 117 In an approach to serine protease inhibitors, Kaura at Glax-oSmithKline developed a Curtius rearrangement approach to C12 amino mutilin derivative 92 (Scheme 21). 118 The approach began with a 1,5-hydride shift dehydroxylation, first reported by Birch, 5 to give 87. Dihydroxylation and oxidative cleavage was followed by oxidation under Jones conditions to give the carboxylic acid 88, which after activation as the acid chloride was treated with sodium azide to form the acyl azide 89. Curtius rearrangement took place in refluxing benzene and the resultant isocyanate was hydrolysed to give a C12 methyl, amino derivative of which 90 is the acetyl amide. Deprotection and oxidation afforded the desired diketone 92 (17% yield) and a mixture of epoxide by-products.
As part of the total synthesis of pleuromutilin by Boeckman, Springer developed a route to the late stage intermediate 96 by degradation of natural pleuromutilin (Scheme 22). Protected mutilin derivative 93 underwent ozonolysis and further oxidation to afford the carboxylic acid 94, which could be eliminated in modest yield either using mercury(II) oxide and iodine or lead(IV) acetate to afford 95. Further ozonolysis of which afforded the ketone 96 in sufficient quantities to investigate installation of the quaternary stereocentre at C12 (vide infra, Scheme 35). 119 Zard developed exciting methodology for direct addition to the C12 vinyl of pleuromutilin in the absence of protecting groups. 120 Treatment of pleuromutilin with a range of xanthates and dilauroyl peroxide (DLP) led to addition of the alkyl xanthate across the olefin to give 97 in moderate to good yields. Whilst Zard suggested that the xanthate in 97 may offer a useful handle for further functionalisation, he also reported two procedures for its removal. Treatment of 97 with DLP or n-Bu 3 SnH gave 98. The use of both DLP and n-Bu 3 SnH gave similar yields, however, DLP may be preferable for the synthesis of medicinal chemistry as tin is avoided (Scheme 23).
Hartwig has reported an iridium-catalysed process for H/D exchange in vinyl groups and has demonstrated its functional group tolerance with a number of complex natural products. Brief exposure of tiamulin (3) to catalyst 101 in benzene-d 6 led to selective labelling of the trans hydrogen to give 99 with only a small percentage of exchange of the cis hydrogen observed (100) (Scheme 24). 121 Exploitation of the reactivity of the C12 vinyl group of mutilin has provided access to a range of novel C12 modified derivatives. Furthermore an appreciation that the reduction product has largely unchanged bioactivity has allowed the use of C12 methyl, ethyl derivatives in chemistry that would be incompatible with the presence of an olefin.
Modification at C13
Introduction of nitrogen functionality at C13 of pleuromutilin was first reported by Berner; thermal decomposition of the saturated C14 carbonazidate 103 resulted in formation of 104 in modest yield as a single undefined diastereoisomer (Scheme 25). 122 Berner reported conversion of 104 to a C13 primary amine analogue of pleuromutilin, however, this required seven steps. Alternatively 104 was converted to 105 by treatment with ZnCl 2 and HCl; thus restoring the pleuromutilin stereochemistry and C3 carbonyl.
In 2011 Uccello at Pfizer reinvestigated the C13 amido mutilin derivative 107 (Scheme 26). 4-epi-Mutilin 12 was treated with sodium cyanate to form carbamate 16, which was used to investigate direct CeH amidation. 123 Regio-and stereoselective amidation was achieved using silver(III) nitrate and 2,4,6-tri-tertbutylpyridine to form 106 in 72% yield. As expected, treatment with ZnCl 2 and HCl restored the pleuromutilin structure and stereochemistry to give 107. Attempts to hydrolyse the oxazolidinone in HCl; h. Ac 2 O, 36% (five steps); i. NaOH, 72%; j. NaIO 4 , RuCl 3 , CCl 4 , 17%.
106 or 107 to access the C13 amino derivative were unsuccessful under basic or mildly acidic conditions. Treatment of 107 with concentrated HCl at 100 C afforded the novel rearranged product 110; the proposed mechanism involved protonation of the alkene to form 108, methyl migration and ring contraction to form keto aldehyde 109, which underwent aldol reaction and oxazolidinone hydrolysis to form 110.
Formation of the C13e14 fused oxazolidinone has been reported using two different routes. Uccello at Pfizer has reported conditions compatible with the C12 vinyl group, however, a scalable procedure for the hydrolysis to C13 amino pleuromutilin has yet to be reported.
Synthetic approaches towards pleuromutilin
Alongside synthetic modification of pleuromutilin, intense effort has focused on access to synthetic cores. This has led to six distinct approaches to the core, three of which relate to complete total syntheses.
Kahn first investigated synthetic access to the core of pleuromutilin in 1980, 124 proposing that the addition of a vinyl anion fragment to spirocyclobutanone 113 and oxy-Cope rearrangement would deliver the skeleton of the natural product 111 (Scheme 27A).
A model study based on forming the 6,8 ring system was undertaken (Scheme 27B). Spiroannulation of cyclohexenone 115 according to the procedure of Trost 125 gave the spirocyclobutanone 116. Addition of vinyl magnesium bromide to the carbonyl group afforded the tertiary allylic alcohol 117, which underwent the desired oxy-Cope [3, 3] sigmatropic rearrangement to give the 6,8 ring system 118 in 35% yield. Subsequent diimide reduction of both the alkene and carbonyl group followed by Jones oxidation gave 119 (Scheme 27B).
In the mid and late 1980s Paquette and co-workers identified advanced intermediates in a proposed asymmetric pleuromutilin synthesis through degradation studies (Scheme 28A). 126e130 The group identified the degradation product 122 and presented a synthetic approach to this lactone, which was then successfully converted into the bicyclic diketone 133 (Scheme 28B). Although this advanced intermediate bore all 20 carbon atoms of the pleuromutilin framework attempts to reconstruct the cyclooctane ring from 133 using a Michael addition were unsuccessful owing to the kinetically unfavourable medium-ring forming cyclisation reaction.
A successful synthetic approach to the tricyclic core of pleuromutilin was published by Zard and co-workers in 2003. 131 Noting the difficulties experienced by Paquette in forming the quaternary centre at C9 at a late stage in the synthesis, Zard proposed formation of a xanthate intermediate 141 (Scheme 29), which could undergo an 8-endo-trig cyclisation.
In order to construct the first cyclisation substrate 137 (Scheme 29), carboxylic acid 136 was prepared from m-ethyl toluate 134 in three steps. From this, the acyl phenyl selenide 137 was synthesised in two steps via the corresponding acid chloride. Cyclisation of 137 gave the desired cis-hydrindanone 138 via 5-exo-trig cyclisation of the acyl radical formed on heating 137 at reflux in heptane in the presence of catalytic ACCN, followed by trapping of the resultant radical with allyltributyltin.
The methylketone 140 was formed from 138 in two steps according to the protocol outlined in Scheme 29. Bromination of the silyl enol ether of 140 was followed by the formation of Oethyl xanthate 141, which underwent 8-endo-trig cyclisation upon treatment with DLP in DCE thus completing a concise construction of the pleuromutilin skeleton 142. Zard suggested that the xanthate may offer a suitable handle for further functionalisation of the pleuromutilin core but also reported cleavage of the xanthate in 80% yield by treating 142 with n-Bu 3 SnH and catalytic AIBN.
The Procter group has reported two approaches to the pleuromutilin core. The first generation approach involved a SmI 2 -mediated cyclisation of readily accessible aldehyde 146 to form the 5,6bicycle 147 and, after further elaboration, ring-closing metathesis (RCM) gave access to the 5,6,8-tricyclic core 149 (Scheme 30). 132e136
Enone 144 was available from 3-ethoxy-2-cyclohexenone 143 in two steps; alkylation and conjugate addition to 144 were followed by trapping of the intermediate enolate with Comins' reagent to afford the vinyl triflate 145. Methoxycarbonylation, deprotection and oxidation afforded the desired cyclisation substrate 146. SmI 2 -mediated cyclisation proceeded with excellent diastereoselectivity and high yield to afford cis-hydrindane 147. The methyl ester was converted to the allylic alcohol 148 which smoothly underwent ring-closing metathesis with Grubbs' second-generation catalyst to give 149. Procter reported further manipulation of the core (149) towards analogues of pleuromutilin: installation of a C12 vinyl group, oxidation to the ketone at C3 and addition of the C14 glycolate ester afforded synthetic pleuromutilin analogue 151.
A second generation approach to pleuromutilin was reported by Procter in 2009; this route gained access to the tricyclic core through a SmI 2 -mediated cascade cyclisation, forming the fiveand eight-membered rings in a single step and setting four contiguous stereocentres with exquisite diastereocontrol (Scheme 31). 137 The cascade cyclisation substrate 154 was constructed from 152 in six steps. In this approach, an allyl silane was introduced through Scheme 28. Synthetic studies towards pleuromutilin using a relay approach by Paquette. Reagents: (A) a. PCC, 86%; b. KOH, EtOH, 83%; c. PCC; d. HS(CH 2 ) 2 SH, p-TsOH, 47% (two steps). (B) a. NaH, DMF, MeI, 81%; b. BrMgCCCH 2 OTHP, 71%; c. H 2 SO 4 , EtOH, 59%; d. HS(CH 2 ) 2 SH, p-TsOH; e. DIBAL, 91% (two steps); f. OCNCH(CH 3 )Ph, DMAP, 128 major 28%, 78% ee; g. HSiCl 3 , Et 3 N, PhCH 3 ; h. CrO 3 , py, 50% (two steps); i. BrMg(CH 2 ) 3 C(OCH 2 ) 2 , 47%; j. p-TsOH, acetone; k. CrO 3 , H 2 SO 4 ; l. HS(CH 2 ) 2 SH, p-TsOH, 58% (three steps); m. LDA, CH 3 CHO; n. CH 3 SO 2 Cl, Et 3 N; o. DBU, 49% (three steps); p. i-PrN(Li)Cy; q. CH 3 I, HMPA, 36% (two steps); r. DIBAL; s. HS(CH 2 ) 2 SH, AlCl 3 , 58% (two steps); t. MeLi; MeI, 90%; u. MeI, H 2 O, 38%; v. EtMgBr, 47%; w. PCC, 99%. conjugate addition. Methoxycarbonylation then afforded 153, which underwent Sakurai allylation to install the remaining carbons of what would become the eight-membered ring. Finally protecting group manipulation and bis-oxidation afforded the dialdehyde 154. SmI 2 -mediated dialdehyde cascade cyclisation proceeded to afford the 5,6,8-tricyclic core in high yield and diastereoselectivity.
Procter went on to report the synthesis of 159, a differentially protected intermediate from Boeckman's total synthesis. Key to the conversion of 155 to 159 was the reduction and deoxygenation of the methylester, this proceeded through the triol 157. A four-step procedure for the processing of this triol to 158 was developed and deoxygenation according to the BartoneMcCombie procedure was reported. Scheme 30. SmI 2 -mediated cyclisation, RCM approach to pleuromutilin core by Procter. Reagents: a. ClMg(CH 2 ) 3 OMgBr; b. TBSCl, im, 66% (two steps); c. LDA, MeI; d. CH 2 ] CH(CH 2 ) 2 MgBr, CuI; Comins' reagent, 72% (two steps); e. Pd(OAc) 2 , CO, Ph 3 P, Et 3 N, MeOH; f. HF, py; g. (COCl) 2 , DMSO, Et 3 N, 78% (three steps); h. SmI 2 , t-BuOH, 80%; i. TBDPSCl, im; j. DIBAL; k. (COCl) 2 , DMSO, Et 3 N, 72% (three steps); l. CH 2 CHMgBr, 89%; m. Grubbs' II, 83%; n. DMP, 79%; o. CH 2 CHMgBr, 86%; p. DIBAL, 90%; q. AcOCH 2 C(O)Cl, Et 3 N; r. HF, py; s. TPAP, NMO, 65% (three steps); t. K 2 CO 3 , MeOH, 91%. R¼TBDPS. Scheme 31. SmI 2 -mediated cascade approach to the core of pleuromutilin by Procter. Reagents: a. TMSCH 2 C(MgBr)CH 2 , CuI; Comins' reagent, 85%, 2.5:1 dr; b. Pd(OAc) 2 , PPh 3 , CO, Et 3 N, MeOH, 88%, 2.5:1 dr; c. TBSO(CH 2 ) 2 CHO, BF 3 $OEt 2 , TBAT, 75%, 2.5:2.5:1:1 dr; d. Ac 2 O, py, DMAP; e. HF, py; f. DMP, 90% (three steps), 2.5:2.5:1:1 dr; g. SmI 2 , t-BuOH, 86%, 2.5:2.5:1:1 dr; h. TBSOTf, Et 3 N, 94%; i. LiAlH 4 ; j. DMP, 2.5:1 dr, major 64% (two steps); k. H 2 , Pd/C, 68%; l. 1,2-ethanediol, HC(OMe) 3 , amberlyst-15; m. LiAlH 4 , 83% (two steps); n. CH 3 C(OCH 3 ) 2 CH 3 , CSA; o. TBSOTf, DMAP, Et 3 N, 94% (two steps); p. PPTS, EtOH, 75%; q. NaH, MBzCl, 77%; r. TCDI; s. n-Bu 3 SnH, AIBN, 72% (two steps). Scheme 29. Radical approach to the core of pleuromutilin by Zard. Reagents: a. Li, NH 3 , t-BuOH, Br(CH 2 ) 3 OTHP; b. H 2 , ClRh(PPh 3 ) 3 , 72% (two steps); c. CrO 3 , H 2 SO 4 , 80%; d. (COCl) 2 ; e. PhSeSePh, NaBH 4 , 75% (two steps); f. AllylSnBu 3 , ACCN, 55%; g. PTSA, CH 3 C(CH 2 OH) 2 CH 3 , HC(OEt) 3 , 85%; h. MeLi, 80%; i. LDA, TMSCl; j. NBS, NaHCO 3 ; k. KSC(S)OEt, 80% (three steps); l. DLP, 60%.
Independently of the work of Procter and co-workers, Sorensen reported a number of approaches to the core of pleuromutilin. Sorensen reported two RCM approaches, either forming the C12e13 or C11e12 bond of the eight-membered ring (Scheme 32). 138 The first approach converted 160 to the cishydrindanone 162 through a series of conjugate additions. Protection of the ketone was followed by borylation of the alkene and palladium-catalysed cross-coupling to install the desired alkene tether. The nitrile 162 was converted to the a,b-unsaturated ketone 163 through a reduction, Grignard addition, oxidation procedure (Scheme 32A). Formation of the eight-membered ring proceeded in this approach in moderate 31e47% yield upon treatment of 163 with the Grubbs' II catalyst.
Alternatively, formation of the C11e12 bond of the eightmembered ring proceeded in 80% yield (Scheme 32B). In this case the key intermediate was accessed through a conjugate addition aldol cyclisation to form 166, followed by addition of cyanide to the a,b-unsaturated ketone. Following protection of the ketone, reduction of the nitrile was followed by addition of methallyl Grignard and protection using the desired glycolate derivative to form 168. RCM using the HoveydaeGrubbs' II catalyst gave access to the core (169) in high yield.
Sorensen has since reported an alternative NozakieHiyamaeKishi (NHK) approach to the tricyclic core of pleuromutilin (Scheme 33A). This route has been used to access the first totally synthetic pleuromutilin analogues that have been assessed for biological activity (Scheme 33B). 139, 140 Excitingly, some of Sorensen's simplified analogues have comparable biological activity to pleuromutilin.
In this approach, common intermediate 167 was subjected to ozonolysis to afford aldehyde 170. The NHK reaction with protected 2-bromoallyl alcohol proceeded in high yield to give a mixture of diastereoisomers (171), allowing later investigation of both epimers at C11. Protecting group manipulation was followed by Appel bromination and reduction of the nitrile to afford bromo-aldehyde 172, which underwent intramolecular NHK reaction to form 173 in moderate yield.
Sorensen has further elaborated 173 to investigate synthetic pleuromutilin and tiamulin analogues; 177 was shown to be the most active analogue, exhibiting identical MIC values to tiamulin against Mycobacterium tuberculosis mc 2 7000. Interestingly this compound is the unnatural epimer at C11.
Total syntheses of pleuromutilin
Two racemic syntheses of pleuromutilin have been reported to date; the first by Gibbons was reported in 1982 and Boeckman followed with his anionic oxy-Cope strategy in 1989. Most recently in 2013, the first non-racemic approach to (þ)-pleuromutilin was reported by Procter. Gibbons' approach was based on the construction of a tetracyclic intermediate 186 (Scheme 34), which could be accessed in 12 steps. 141, 142 The bridged cis-hydrindane ring system 180 was constructed via sequential Michael reaction of 178 and 179. A series of organolithium additions and oxidations gave 182, which was hydrogenated to give 183 as a 3:1 mixture of diastereoisomers. Aldol condensation of 183 gave 184, which was converted into the key intermediate 186 through epoxidation, ring opening and protection (Scheme 34).
With the key tetracyclic intermediate in hand, Gibbons had proposed a retro-aldol reaction to afford the desired bond cleavage to diketone 188. However, this reaction was unsuccessful and the transformation was instead achieved via a Grob-type fragmentation promoted by N-bromoacetamide to form 187, which was followed by a zinc-mediated reduction to diketone 188 (Scheme 34).
Gibbons then began the task of modifying the functionality on the tricyclic core to complete the synthesis in a further 17 steps. Removal of the carbonyl on the six-membered ring was achieved in three steps by reduction to the diol, which was selectively mesylated and reduced to afford 189. The stereochemistry at C14 at this stage was opposite to the natural product and epimerisation was achieved using an oxidation/reduction sequence. Protection and ozonolysis of 190 gave 191 (Scheme 34); this key intermediate was also used in the route of Boeckman's group (vide infra, Scheme 35).
Formation of the quaternary centre at C12 from ketone 191 was the final significant challenge in the first synthesis of pleuromutilin. Gibbons stated that methods that formed a carbanion at C12 result in elimination of the C11 hydroxyl and methods which relied upon carbonium ion character at C12 also proved unsuccessful. Thus Gibbons formed the a,b-unsaturated aldehyde and reduced it to the allylic alcohol 192. g-Alkylation of 192 gave exclusively the desired epimer 193 according to Murahashi's procedure. 143 Allylic alcohol 192 was recovered (20% yield) and the product resulting from aalkylation was also formed (20% yield) in this key step.
The C3 carbonyl group was installed by benzyl deprotection followed by oxidation. Cleavage of the methoxymethyl ether protecting groups completed the first racemic total synthesis of mutilin, which was converted to pleuromutilin by bis-glycolic ester formation and mild hydrolysis (Scheme 34).
Boeckman proposed an approach to pleuromutilin involving the construction of the tricyclic skeleton 199 devoid of most of the required functionality and stereochemistry (Scheme 35). Elaboration of this skeleton would then be carried out, with the relative stereochemistry being controlled by the conformation of the ring systems, as predicted by MM2 calculations. 119,144e146 Boeckman envisioned formation of the tricyclic core via an oxy-Cope rearrangement of bridged tricyclic intermediate 198. 195 (Scheme 35). Following functional group manipulation, tricycle 197 was formed via 1,6-conjugate addition/intramolecular enolate alkylation. Addition of vinyl Grignard to 197 proceeded with no stereochemical preference; the desired epimer 198 was isolated in 43% yield and the undesired diastereoisomer was equilibrated to a mixture of diastereoisomers (dr 1:1) by treatment with phenylsulfenyl chloride and triethylphosphite in methanol. The pleuromutilin skeleton 199 was successfully formed via an anionic oxy-Cope rearrangement of 198 in exceptionally high yield (Scheme 35).
Following the synthesis of 199, studies to introduce the required functionality began. Epoxidation of 199 was followed by rearrangement to install the C3 carbonyl and subsequent ketalization gave 200. The C3 carbonyl group was reduced and protected as the benzyl ether before treatment with PyHBr 3 afforded the equatorial bromo-ketal, this underwent syn-elimination to the E-alkene 202. Treatment of 202 with p-toluenesulfonic acid in wet acetone heated to reflux installed the C14 hydroxyl, which was protected as the MOM ether 203.
Extensive work was carried out on the optimisation of C11 oxidation to form 191. 119 The formation of silyl enol ethers using either TMSCl and LDA or TBSOTf and Et 3 N both gave mixtures of silyl enol ethers and therefore upon epoxidation and rearrangement mixtures of C11 and C13 silyloxy products. However, the conditions shown in Scheme 35 for the Rubottom-type oxidation selectively installed the C11 hydroxyl as a single epimer. Protection as the MOM ether gave access to Gibbons' intermediate 191 (vide supra, Scheme 34) .
At this stage the development of methods for the introduction of the quaternary centre at C12 from ketone 191 began. To provide additional material to carry out their studies, a route to 191 from natural mutilin was developed (vide supra, Scheme 22); this sevenstep protocol provided sufficient material to develop the final steps of the synthesis before carrying out the transformations only once on valuable, totally synthetic material.
Simplified model studies for a Wittig-based route looked promising, however, no Wittig reaction was successfully carried out on 191; the C12 carbonyl is believed to be too sterically crowded.
Addition of vinyl Grignard to 191 followed by treatment of the resultant, inconsequential 7:1 diastereoisomeric mixture of allylic alcohols with thionyl chloride and triethylamine gave allylic chloride 204. Initially Boeckman proposed access to 193 by cyclopropanation and rearrangement of an allylic silane, however, attempts to convert 204 to the allylic silane resulted in g-addition of silicon to give 205 (Fig. 3 ). 3 , 50% (three steps); w. Li, NH 3 ; x. PCC; y. HCl/EtOH, 80% (three steps); z. AcOCH 2 COOMs, DMAP; a 0 . KOH, MeOH, 39% (two steps). The possibility of g-alkylation of 204 was next investigated.
Addition of lithium dimethylcuprate to 204 yielded a 2.6:1 mixture of a-alkylation product 207 and diene 206 ( Fig. 3) . No g-alkylation product was observed. Addition of lithium cyano(methyl) cuprate in HMPA and THF gave the desired g-alkylation product 193 as the major product in a 2:1:1 mixture with 206 and 207, respectively. Alkylation with a 1:1 complex of methyl copper and triethyl boron had been reported by Yamamoto et al. 147 and gave exclusively galkylation, however in this system a 1.8:1 mixture of ethyl and methyl addition was observed. Finally treatment of allylic chloride 204 with CH 3 CuB(CH 3 ) 3 afforded a 5:1 mixture of 193 and 207 in 93% yield.
At this stage attention was turned to conversion of 193 to mutilin (2) and ultimately to pleuromutilin (1) . Mutilin was used to produce protected triol 193, such that these final steps could be investigated. Despite this investigation and the construction of differentially protected analogues of 193, Boeckman found Gibbons' endgame to provide the best approach to pleuromutilin.
In 2013 Procter reported the first non-racemic synthesis of (þ)-pleuromutilin. The key steps of the synthesis are the SmI 2mediated cascade cyclisation to form the 5,6,8-tricyclic core and the SmI 2 eamineeH 2 O-mediated reduction of a very hindered methyl ester. Non-racemic cascade substrate 213 was available from the chiral pool starting material 208 in eight steps according to the procedure shown in Scheme 36. 148 A series of conjugate additions were followed by methoxycarbonylation of a vinyl triflate to afford 210 as a 2.5:1 mixture of diastereoisomers. Sakurai allylation was used to install the remaining carbons required for the cascade substrate and protecting group manipulation and oxidation gave 213; in this case the pivaloyl protection was reported to give a more stable dialdehyde. SmI 2 -mediated cascade cyclisation of 213 proceeded in excellent yield and with very high diastereocontrol to give the desired tricyclic core of pleuromutilin 214.
Following protecting group manipulation and oxidation of 214, ketone 215 was reported as a single diastereoisomer and enantiomer in >98% ee. Reduction of the olefin 215 proceeded in near quantitative yield to give a separable 3:1 mixture of diastereoisomers; the major ketone 216 was protected with concomitant removal of one silyl ether to give 217. SmI 2 eamineeH 2 Omediated reduction of 217 proceeded in 95% yield using pyrrolidine as a crucial, activating Lewis basic additive. 149 Selective protection of the resultant diol was reported to form 218. This route avoided the protecting group chemistry necessary to process triol 157 (vide Scheme 36. Total synthesis of (þ)-pleuromutilin by Procter. Reagents: a. BrMgCH 2 CH 2 CH 2 OTBS, CuCN$2LiCl, TMSCl; b. Pd(OAc) 2 , O 2 , 85% (two steps); c. TMSCH 2 C(MgBr)CH 2 , CuI; Comins' reagent, 85%, 2.5:1 dr; d. Pd(OAc) 2 , PPh 3 , CO, MeOH, Et 3 N, 85%, 2.5:1 dr; e. TBSOCH 2 CH 2 CHO, BF 3 $OEt 2 , TBAT, 73%, 2.5:2.5:1:1 dr; f. PivCl, py, DMAP; g. HF, py; h. DMP, 88% (three steps), 2.5:2.5:1:1 dr; i. SmI 2 , t-BuOH, 88%, 2.5:2.5:1:1 dr; j. TBSOTf, Et 3 N, 76%, 2.5:2.5:1:1 dr; k. LiAlH 4 ; l. DMP, 63%, >98:2 dr, >98% ee; m. H 2 , Pd/C, 75%; n. 1,2-ethanediol, HC(OMe) 3 , Amberlyst Ò 15, 96%; o. SmI 2 , pyrrolidine, H 2 O, 95%; p. LDA, MBzCl, 77%; q. TCDI; r. nBu 3 SnH, AIBN, 66% (two steps); s. FeCl 3 $SiO 2 , 99%; t. TMSI, HMDS; u. m-CPBA, NaHCO 3 ; v. TBAF, 94% (three steps); w. HF, 78%; x. MOMCl, DIPEA, 75%; y. EtOCHCHSnBu 3 , n-BuLi; z. FeCl 3 $SiO 2 ; a 0 . NaBH 4 , H 2 O, 63% (three steps); b 0 . NCS, DMS, 97%; c 0 . CuCN, Me 2 Zn, 71%; d 0 . LiAlH 4 ; e 0 . DMP; f 0 . AcCl, EtOH, 69% (three steps); g 0 . trifluoroacetylimidazole; h 0 . trifluoroacetoxyacetic acid, EDCI, DMAP; MeOH, Et 3 N, 75% (two steps). supra, Scheme 31). Procter then reported the deoxygenation of 218 to afford 219 via the thioimidazolide according to the Bar-toneMcCombie procedure.
Following deprotection of the ketal, Rubottom oxidation according to the procedure of Boeckman installed the C11 hydroxyl both regio-and diastereoselectively to give 220. The authors where unable to construct the C12 methyl, vinyl stereocentre in the presence of the C14 silyl ether and also reported lower selectivity for the Rubottom oxidation with MOM protection on the C14 hydroxyl, in line with the observations of Boeckman. They therefore converted 220 to the bis-MOM ether 221 in two steps and constructed the methyl, vinyl stereocentre by a modification of both the Gibbons and Boeckman methods. Allylic chloride 222 was, in this case, constructed by addition of a lithiated enol ether to ketone 221, the inconsequential mixture of diastereoisomers was hydrolysed to the a,b-unsaturated aldehyde, which was then reduced to the allylic alcohol before CoreyeKim chlorination gave 222. S N 2 0 Alkylation of 222 was achieved using Me 2 Zn and CuCN in DMF, delivering the methyl both regio-and diastereoselectively to form 223 in 71% yield.
Progression of 223 to (þ)-mutilin (2) was described in three steps according to standard procedures that are shown in Scheme 36. Efficient conversion of mutilin (2) to pleuromutilin (1) was previously unreported in the literature. The Gibbons approach relied upon multiple iterations and the yield reported by Boeckman was low (39%). The use of C11 trifluoroacetate protection was, however, known for the synthesis of C14 analogues of pleuromutilin and the group of Procter utilised this methodology to finish the total synthesis. Treatment of (þ)-mutilin (2) with trifluoroacetylimidazole at reduced temperature gave C11 trifluoroacetylmutilin, which underwent efficient EDCI coupling with trifluoroacetoxyacetic acid. It was shown that quenching the reaction with methanol and treatment with triethylamine led to the cleavage of both trifluoroacetate groups and delivered (þ)-pleuromutilin (1) in 75% for the last two steps.
To date three strategically very different total syntheses of pleuromutilin have been reported, with surprisingly similar step counts. Each offers different insights into the construction and functionalisation of this unique and beautiful natural product. Gibbons' fragmentation approach elegantly constructs a highly functionalised tricyclic core, which is further elaborated to the natural product in a total of 31 steps. Boeckman's route, by far the shortest (27 steps), relies upon late stage functionalisation of a largely unfunctionalised core constructed by a [3,3]-sigmatropic rearrangement. Importantly, the work of Boeckman's group has taught the community much about the functionalisation of the core, through experimentation and calculation. Procter's synthesis is the first to gain access to (þ)-pleuromutilin and involves a remarkable cascade cyclisation constructing four contiguous stereocentres and two new rings in a single step, the group went on to report the first efficient conversion of mutilin to pleuromutilin.
Conclusions
Industrialists and academics alike have been inspired by pleuromutilin since its first isolation 63 years ago, yet, only three pleuromutilin derivatives grace the market. A vast amount is now understood about the SAR surrounding the C14 side chain and semi-synthesis has provided some modifications to the core. However, these efforts have not resulted in new treatments. Semi-synthetic analogues are still under investigation and synthetic approaches to the core, reported over the last 5 years, promise to offer novel totally synthetic analogues, which may become key weapons in the ongoing battle against antimicrobial resistance.
